Coagulation Analyzers Market

• The leading Coagulation Analyzers companies working in the Coagulation Analyzers Market include Abbott Laboratories Inc., Siemens Healthcare GmbH, Sysmex Corporation, Thermo Fisher Scientific Corporation, F. Hoffmann-La Roche Ltd., HORIBA Medical, Nihon Kohden Corporation, Maccura Biotechnology Co., Ltd., Bio-Group Medical System, Genrui Biotech Inc., A&T Corporation, Stago Group, Beijing Succeeder Technology Inc., Helena Laboratories Corporation, BPC BioSed S.R.L., Meril Life Sciences Pvt. Ltd., SCLAVO Diagnostics International, Erba Group, ACON Laboratories, Inc., Haemonetics Corporation, and others.
• According to the Haemophilia Foundation Australia, 2024, more than 7,400 people in Australia have been diagnosed with a bleeding disorder. As per same statistics, more than 2,500 people have been diagnosed with VWD in Australia, but many more are thought to be undiagnosed. It affects both females and males from all racial backgrounds.

Coagulation Analyzers Market by Product (Instruments [Automated Analyzers, Semi-Automated Analyzers, Manual Analyzers], Reagents and Consumables), Coagulation Analyzers Market by Test Type (Fibrinogen Testing, Activated Clotting Time Testing (ACT), D-Dimer Testing, Platelet Function Testing, Others), Coagulation Analyzers Market by Technology (Optical Technology, Mechanical Technology, Electrochemical Technology, Others), Coagulation Analyzers Market by End-User (Hospitals, Diagnostic Centers, and Others), and Coagulation Analyzers Market by Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a substantial CAGR forecast till 2030 owing to the increasing instances of bleeding disorders and the rising product developmental activities across the globe.

The Coagulation Analyzers market was valued at USD 4.19 billion in 2023, growing at a CAGR of 5.44% during the forecast period from 2024 to 2030 to reach 5.74 billion by 2030. The coagulation analyzers market is experiencing significant growth due to the rising prevalence of chronic bleeding disorders such as hemophilia and von Willebrand disease (VWD), continuous advancements in analyzer technology, and addressing the complex needs of individuals with bleeding disorders that are acting as major factors contributing to the overall growth of the coagulation analyzers market during the forecast period from 2024 to 2030.

Coagulation Analyzers Market Dynamics:

The coagulation analyzers market is witnessing growth owing to various factors, one of the key factors being the growing prevalence of cardiovascular diseases.

According to the World Federation of Haemophilia (2022) reports, approximately 20,000 people with hemophilia are born each year worldwide, with about 7,000 of these cases being classified as severe. In addition to this, it was reported that there are 233,577 individuals with hemophilia, comprising 185,318 with Hemophilia A and 37,998 with Hemophilia B. 

According to the Haemophilia Foundation Australia, 2024, more than 7,400 people in Australia have been diagnosed with a bleeding disorder. As per same statistics, more than 2,500 people have been diagnosed with VWD in Australia, but many more are thought to be undiagnosed. It affects both females and males from all racial backgrounds.

Chronic blood disorders have a significant impact on the health and quality of life of patients and their families. They can cause pain, loss of normal functioning, depression, and anxiety, financial burden, long-term hospitalization, and even death. Therefore, to properly treat and manage chronic blood disorders like Haemophilia and VWD, coagulation analyzer devices are required. These devices help to detect clotting deficiencies, measure coagulation pathways speed, thrombolin levels and are also used to monitor the effects of drugs in blood.

In addition, key Coagulation Analyzers companies operating in the market are focusing on developing advanced technologically based coagulation analyzer devices. For instance, in May 2024, Haemonetics Corporation gained 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its TEG 6s Hemostasis Analyzer System with the new Global Hemostasis-HN assay cartridge. This latest addition to the TEG 6s system expanded its capabilities in viscoelastic testing, specifically designed to improve assessment for patients who are fully heparinized during adult cardiovascular surgeries and liver transplants.

Hence, the interplay of all the above-mentioned factors are expected to drive the market for coagulation analyzers market during the given forecast period from 2024 to 2030.

However, their results can be affected by various factors, such as sample quality & anticoagulants, availability of alternative procedures and others that may restrict the market growth.

Coagulation Analyzers Market Segment Analysis:

Coagulation Analyzers Market by Product (Instruments [Automated Analyzers, Semi-Automated Analyzers, Manual Analyzers], Reagents and Consumables), Coagulation Analyzers Market by Test Type (Fibrinogen Testing, Activated Clotting Time Testing (ACT), D-Dimer Testing, Platelet Function Testing, Others), Coagulation Analyzers Market by Technology (Optical Technology, Mechanical Technology, Electrochemical Technology, Others), Coagulation Analyzers Market by End-User (Hospitals, Diagnostic Centers, and Others), and Coagulation Analyzers Market by Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product segment of the coagulation analyzers market, the automated analyzers category is expected to have a significant revenue share in the year 2023. This is because automated coagulation analyzers offer a range of advanced features and applications that enhance their utility in both clinical and research settings. These analyzers are designed to streamline the assessment of blood coagulation, providing rapid and accurate measurements of various clotting factors.

Key features of automated analyzers include automated sample handling, which reduces manual intervention and minimizes errors, and high-throughput capabilities that enable simultaneous testing of multiple samples. These often incorporate sophisticated algorithms for comprehensive analysis of coagulation pathways, thrombolin levels, and platelet function. Automated analyzers also offer integrated data management systems that facilitate real-time monitoring, result tracking, and reporting, which are crucial for managing complex bleeding disorders.

Automated analyzer’s applications span from routine diagnostic testing in hospitals and laboratories to specialized monitoring during surgeries and treatment adjustments for chronic conditions. By enhancing efficiency and precision, automated coagulation analyzers play a critical role in improving patient outcomes and optimizing treatment strategies.

Therefore the widespread uses and various advantages of automated analyzers enhance performance and usability solidifying a significant impact on the growth of the overall coagulation analyzers market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall Coagulation Analyzers Market:

Among all the regions, North America Coagulation Analyzers market is estimated to hold a significant revenue share in the Coagulation Analyzers market. This growth in the coagulation analyzers market can be attributed to several factors, including the rising prevalence of hemophilia and related complications, ongoing advancements and regulatory clearances for innovative devices, and the strong presence of key Coagulation Analyzers companies with robust distribution networks. Combined with well-established healthcare infrastructure and supportive reimbursement programs, these factors drive the increasing adoption and revenue growth of coagulation analyzers in the region from 2024 to 2030.

According to data from the Centers for Disease Control and Prevention (2024), it stated that currently in the US, an estimated 33,000 males are living with hemophilia. Hemophilia A, characterized by low levels of clotting factor VIII, is three to four times more common than hemophilia B, which is associated with low levels of clotting factor IX. The median age at diagnosis varies by the severity of the condition: 36 months for mild hemophilia, 8 months for moderate hemophilia, and 1 month for severe hemophilia. Furthermore, nearly 75% of men with hemophilia have a history of prior hepatitis C virus (HCV) infection, and approximately 25% have a history of human immunodeficiency virus (HIV) infection.

As per the National Hemophilia Foundation 2021, between 30,000-33,000 people were living with hemophilia in the US.

Coagulation analyzers play a crucial role in the treatment of hemophilia by providing detailed assessments of blood clotting function. These devices enable health care providers to monitor and evaluate the efficacy of treatment regimens and adjust therapies based on real-time data. For individuals with hemophilia, analyzers help in tailoring factor replacement therapy, optimizing bleeding risk management, and assessing the impact of concurrent infections or complications.

Various product developmental strategies such as clearances in the region by regulatory authorities in the region play a major role in pushing forward the revenue shares of coagulation analyzers in the region. For example, in July 2023, Siemens Healthcare GmbH received FDA clearance for the Atellica CI Analyzer, designed for both immunoassay and clinical chemistry testing. It offers significant benefits including enhanced turnaround time predictability, advanced reporting capabilities, and targeted safety and security features. For coagulation analysis, the Atellica CI Analyzer's advanced technology ensures precise and reliable results, supporting efficient and effective laboratory operations.

Additionally, in April 2024, Haemonetics Corporation announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its TEG® 6s Hemostasis Analyzer System Global Hemostasis-HN Assay Cartridge. This new cartridge enhances the TEG 6s system’s viscoelastic testing capabilities, enabling it to effectively assess hemostasis in fully heparinized patients undergoing adult cardiovascular surgeries, procedures, and liver transplantation. The expanded functionality supports both laboratory and point-of-care applications, offering improved management of coagulation in complex clinical scenarios.

The prompt and well-established healthcare services and infrastructure further contribute to the growth of the regional coagulation analyzers market growth. The presence of key Coagulation Analyzers companies such as Abbott Laboratories Inc and Thermo Fisher Scientific Corporation with their strong distribution networks ensure widespread availability and accessibility of these devices across the region increasing their revenue shares in the market, and supportive reimbursement programs providing immense growth opportunities for the same.

Therefore, the interplay of all the factors mentioned above would provide a conducive growth environment for the North America region in the coagulation analyzers market during the forecast period from 2024 to 2030.

Key Coagulation Analyzers Companies In The Market:

Some of the key market players operating in the Coagulation Analyzers market include Abbott Laboratories Inc., Siemens Healthcare GmbH, Sysmex Corporation, Thermo Fisher Scientific Corporation, F. Hoffmann-La Roche Ltd., HORIBA Medical, Nihon Kohden Corporation, Maccura Biotechnology Co., Ltd., Bio-Group Medical System, Genrui Biotech Inc., A&T Corporation, Stago Group, Beijing Succeeder Technology Inc., Helena Laboratories Corporation, BPC BioSed S.R.L., Meril Life Sciences Pvt. Ltd., SCLAVO Diagnostics International, Erba Group, ACON Laboratories, Inc., Haemonetics Corporation, and others.

Recent Developmental Activities in the Coagulation Analyzers Market:

• In February 2021, Horiba Medical announced that its new generation of the Microsemi CRP hematology analyzer, the Microsemi CRP LC-767G, received CE marking. The new analyzer is more compact with enhanced software and network connectivity with higher memory. It also includes a new parameter, the Granulocytes-to-Lymphocytes Ratio.
• In January 2021, PixCell Medical announced that it signed a distribution agreement for its HemoScreen Hematology Analyzer in Sweden with Triolab. HemoScreen is a portable, point-of-care complete blood count analyzer that uses disposable cartridges that include all necessary reagents and provides results from a single drop of blood from a fingerstick.

Key Takeaways from the Coagulation Analyzers Market Report Study

• Coagulation Analyzers Market size analysis for current coagulation analyzers market size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key Coagulation Analyzers companies dominating the coagulation analyzers market
• Various opportunities available for the other competitors in the coagulation analyzers market space
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current coagulation analyzers market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for coagulation analyzers market growth in the coming future?

Target Audience who can be benefited from this Coagulation Analyzers Market Report Study

• Coagulation analyzer device providers
• Research organizations and consulting companies 
• coagulation analyzers related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in coagulation analyzers 
• Various end-users who want to know more about the coagulation analyzers market and the latest developments in the coagulation analyzers market

Get detailed insights @ DelveInsight Blogs